Online Now: Subclonal immune evasion in non-small cell lung cancer dlvr.it/TLkxG2

Excited to share our new paper with Sheila's lab: we performed an in vivo genome-wide CRISPRa screen using a lung TRACERx PDX model to uncover drivers of brain metastasis. BACE1 emerged as a key hit - especially interesting given ongoing therapeutic efforts in Alzheimer’s.

CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic clones in blood—especially TET2 mutant ones—migrate into tumors, reshape immunity, drive progression, and promote recurrence. The ability of a somatic clonal expansion in the hematopoietic compartment, to regulate malignant progression in another tissue represents a new perspective in cancer biology. #CHIP #LCMS #cancer #biology #AACR25 nejm.org/doi/full/10.1056/NE…

Great to see this collaborative paper out @NatureComms. @TimWitney's team developed a PET radiotracer that distinguishes high/low NRF2 antioxidant pathway activation, including in our @CRUKLungCentre PDX models. Congrats @hgreenwood93 and team! 👏 nature.com/articles/s41467-0…

🚨So proud to present the first study from our @CCG_UCL group together with @CharlesSwanton @NnennayaKanu and led by @ojlucas with key collaboration @Ward__Sophie and fundamental support @Rija_Zaidi_ @abi_bunkum & many others Out in @NatureGenet 👇 doi.org/10.1038/s41588-024-0… 🧵👇

Our TRACERx non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models are now available through CancerTools.org 🎉 A big thank you to Dave Pearce and the incredible @CRUKLungCentre team who have made this possible!

Is Osimertinib over? Not at all IMO. We just need to think more deeply about patient selection. I’ll point (again) to our recent paper looking at Genome Doubling and TP53 in EGFR positive NSCLC with @swantonlab nature.com/articles/s41467-0…

Today our study of the association between replication timing alterations and mutation acquisition during cancer evolution has been published in @NatureComms nature.com/articles/s41467-0…

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in @NatureComms. nature.com/articles/s41467-0… 🧵

Patient-derived xenograft (PDX) models allow cancer researchers to study tumour tissue from patients in mice. Our @CRUKLungCentre paper @NatureComms describes 48 new PDX models and highlights the importance of intratumor heterogeneity in the development of cancer models (1/9)

Comment: Capturing heterogeneity in PDX models: representation matters nature.com/articles/s41467-0…

This study highlights the importance of considering primary tumor heterogeneity when using PDX models and emphasizes the benefit of comprehensive tumor sampling nature.com/articles/s41467-0…

New review out in @trendscancer from Chris Abbosh and @CharlesSwanton. Excellent summary of latest evidence & use case for ctDNA in NSCLC at diagnosis/landmark timepoints to help with staging and decisions around adjuvant treatment - worth reading #LCSM sciencedirect.com/science/ar…

Patient-derived xenograft (PDX) models are widely used and valuable tools in #CancerResearch. But there are limitations to how well these models can represent the genetic complexity of patient tumours @robhynds @SwantonLab buff.ly/4aNLqDh @CRUKresearch @TheCrick @uclnews

My @SwantonLab postdoc paper is now out @NatureComms. It was a huge privilege to work with the TRACERx team. Thanks to @AMIHuebner and Dave Pearce, as well as everyone else @uclcancer, @TheCrick and @CRUK_MI who made this happen.

Extremely grateful and excited to have support from @CRUKresearch to work on cancer initiation with @SwantonLab @TheCrick! Ever grateful to @drjkrane @AFrankell for the supervision and mentorship

It has been great to collaborate with @hgreenwood93, @TimWitney and team on their investigation of a new PET-based approach for imaging NRF2 activation in NSCLC. A tour de force across cell lines, GEMMs and @CRUKLungCentre PDX models!

Absolutely stoked that 'Bug in the System: The past, present and future of cancer' has been picked up for Seriously - always a must-listen in my podcast app. Check out all 3 episodes here: bbc.co.uk/programmes/m001p6r… #scicomm #cancer #cancerresearch #immunotherapy

Come start your group at the Crick! 💡 We're looking for creative early career researchers in cardiac and vascular biology, or clinician scientists in any field, to join our faculty community. #AcademicJobs | #ECRChat Apply by 5 October ⬇️ crick.ac.uk/careers-study/fa…

Thank you @DrSidMukherjee for taking the time out of your busy schedule to visit @SwantonLab @WillHilliam @DrClareWeeden @CharlesSwanton to talk about our work on air pollution and lung cancer @TheCrick